Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
NAALAD2
REST API REST API
Homo sapiens
NAALAD2 is differentially expressed in 183 experiments: 116 organism parts: pituitary gland, lung, ... (114 more);, 120 disease states: normal, healthy, ... (118 more);, 61 cell types 174 cell lines 14 compound treatments and 70 other conditions.
Synonyms NAALADASE2, NAADALASE2, GPCIII
Orthologs FOLH1 (Danio rerio)   Naalad2 (Mus musculus)   ENSCING00000005093 (Ciona intestinalis)   NAALAD2 (Bos taurus)   NAALAD2 (Gallus gallus)   Q69HT2_CIOIN (Ciona intestinalis)   ENSCING00000015937 (Ciona intestinalis)   VPS70 (Saccharomyces cerevisiae)   ENSCING00000005372 (Ciona intestinalis)   Naalad2 (Rattus norvegicus)   naalad2 (Xenopus laevis)   NAALAD2 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term dipeptidase activity, membrane, metallopeptidase activity, peptidase activity, metal ion binding, neurotransmitter catabolic process, serine-type peptidase activity, dipeptidyl-peptidase activity, proteolysis, integral to membrane, carboxypeptidase activity
InterPro Term Peptidase_M28, Protease-assoc_domain, TFR-like_dimer_dom
UniProt Accession Q9Y3Q0, Q4KKV4, E9PII2, E9PJ53, E9PJV2, E9PKX5
Search EB-eye ENSG00000077616
Show more properties
Experimental Factors
Organism part

studied in E-AFMX-5, E-GEOD-6573, E-MEXP-1251, E-MTAB-24, E-MTAB-25, ... (19 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-22152, E-GEOD-19639, E-GEOD-24147, ... (20 experiments)

Factor Value U/D Experiments
KG1
2
E-MTAB-37, E-GEOD-24147
MCF-7
2
E-GEOD-5823, E-GEOD-19639
22Rv1
1
1
E-MTAB-37
BC2
1
E-MTAB-37
HCC1954
1
E-MTAB-37
CAL62
1
E-MTAB-37
168 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-MEXP-66, E-GEOD-20677, E-GEOD-4219, ... (36 experiments)

Factor Value U/D Experiments
fibroblast
2
E-GEOD-3920, E-GEOD-26672
induced pluripotent stem cell
2
E-GEOD-18147, E-GEOD-18265
effector memory T cell
1
E-GEOD-3982
chondrocyte
1
E-TABM-130
activated B-cell
1
E-MEXP-2360
B cell
3
1
E-GEOD-13987
55 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-MEXP-1121, E-MEXP-2069, E-GEOD-5563, ... (33 experiments)

Factor Value U/D Experiments
breast carcinoma
2
E-MTAB-37, E-TABM-276
lung adenocarcinoma
2
E-MTAB-62, E-MTAB-37
neuroblastoma
2
E-MTAB-37, E-MTAB-62
prostate carcinoma
2
E-MTAB-62, E-MEXP-2034
lung cancer, cytotoxicity
1
E-MTAB-62
Nodular Goiter
1
E-MEXP-2442
114 more value(s).


Compound treatment

studied in E-MEXP-1269, E-GEOD-3284, E-GEOD-412, E-GEOD-5230, E-MEXP-2241, ... (8 experiments)

Factor Value U/D Experiments
none
2
E-GEOD-412, E-GEOD-4600
ethanol
1
E-MEXP-2241
Cxcl12
1
1
E-GEOD-7307
5-aza-2'-deoxycytidine + trichostatin A
1
1
E-MEXP-1269
glutamine
1
E-MEXP-941
anti-CD3
1
1
E-GEOD-7307
8 more value(s).


A rna yield

studied in E-TABM-325

Factor Value U/D Experiments
110.33
1
1
E-TABM-325
132.96
1
1
E-TABM-325
138.36
1
1
E-TABM-325


Age at diagnosis
studied in E-GEOD-21653

Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-21589, E-GEOD-16363

Clinical info
studied in E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-MEXP-1251, E-GEOD-21374, ... (10 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-MEXP-2359, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-22544, E-GEOD-3325, E-GEOD-21138, E-GEOD-21887 ... (5 experiments)

Environmental stress
studied in E-GEOD-1643

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-MTAB-108

Genotype
studied in E-GEOD-3494, E-GEOD-2466

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1446, E-GEOD-9764, E-MEXP-1103, E-MEXP-1741, ... (7 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-MEXP-2069, E-TABM-666, E-GEOD-19519, ... (21 experiments)

Infection
studied in E-GEOD-12108, E-MEXP-561

Ki67 ihc
studied in E-GEOD-21653

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-TABM-130, E-MEXP-958, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-21750, E-GEOD-4600

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

Replicate
studied in E-GEOD-10797

Rna integrity
studied in E-TABM-325

RNAi
studied in E-GEOD-12438, E-GEOD-3697, E-MEXP-1857, E-MEXP-2759

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374

Sex
studied in E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Treatment
studied in E-GEOD-16837, E-GEOD-19246

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Ttf
studied in E-GEOD-21521

Tumor grading
studied in E-GEOD-4922

Processing time: 0.346 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM